Form 4: BioLife Solutions Executive Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions, sold 328 shares of common stock on January 6, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions, executed a sale of 328 shares of common stock.
- The transaction occurred on January 6, 2025, at a price of $27.02 per share.
- The sale was conducted under a Rule 10b5-1(c) trading plan adopted by Ms. Foster on January 3, 2023.
- This plan was established to cover tax withholding obligations related to the vesting of restricted stock.
- Following the transaction, Ms. Foster directly owns 156,645 shares of BioLife Solutions common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction under a pre-existing plan, with no indication of positive or negative sentiment. It is a neutral event.
Risks
- Sales by company executives can sometimes be perceived negatively by the market, although this sale was pre-planned.
Industry Context
Executive stock sales are a common occurrence, and the use of 10b5-1 plans is a standard practice to avoid accusations of insider trading. This transaction is not unusual for a company of this size and stage.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among publicly traded companies to allow insiders to sell shares without the risk of insider trading accusations.
- Many executives at comparable biotech and life sciences companies use similar plans for tax and diversification purposes.
- The volume of shares sold is relatively small compared to the total shares owned by the executive, suggesting this is a routine transaction.
Stakeholder Impact
- The sale is unlikely to have a significant impact on shareholders, as it was a small transaction under a pre-arranged plan.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Date the 10b5-1 trading plan was adopted by Karen A. Foster. |
| 01/06/2025 | Date of the stock sale transaction. |
| 01/08/2025 | Date the Form 4 was signed. |
Keywords
BioLife Solutions, BLFS, insider trading, Form 4, stock sale, 10b5-1 plan, executive, Karen A. Foster, share sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.